

University of Groningen

## Rational Selection of valved holding chambers in the treatment of COPD or Asthma by means of the system of objectified judgement analysis

Hagedoorn, Paul; Dekhuijzen, Richard; Kooistra, Johan ; Janknegt, Robert

*Published in:*  
ACTA Scientific Pharmacology

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2021

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Hagedoorn, P., Dekhuijzen, R., Kooistra, J., & Janknegt, R. (2021). Rational Selection of valved holding chambers in the treatment of COPD or Asthma by means of the system of objectified judgement analysis. *ACTA Scientific Pharmacology*, 3(1), 46-53.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# Rational Selection of Valved Holding Chambers in the Treatment of COPD or Asthma by Means of the System of Objectified Judgement Analysis

Acta Scientific Pharmacology 3.1 (2022): 46-53.

Received: December 13, 2021. Published: December 31, 2021.

© All rights are reserved by Robert Janknegt, et al.

## Authors

Paul Hagedoorn<sup>a</sup>,  
Richard Dekhuijzen<sup>b</sup>,  
Joban Kooistra<sup>c</sup> and  
Robert Janknegt<sup>a\*</sup>

\*Corresponding Author:  
Robert Janknegt,  
Hospital Pharmacist,  
Clinical Pharmacologist  
Sittard, The Netherlands.

## Abstract

**Valved inhalation chambers are important instruments to increase the available dose of pressurized metered dose inhalers, in this study inhalation chambers are compared by means of the System of Objectified Judgement Analysis (SOJA) method. The SOJA method is a model for rational drug selection. The relevant selection criteria for inhalation chambers are defined and judged by a panel of experts and each selection criterion is given a relative weight. The following inhalation chambers were included: Aerochamber, Inspirachamber, Optichamber, Volumatic and Vortex. Selection criteria were: Transparency, Feedback system in case of too forceful inhalation, Antistatic properties, Dose delivery, Availability of mouth masks, Easy to carry, Suitability for children and inclusion in Summaries of Product Characteristics of metered dose inhalers.**

**Aerochamber showed by far the highest score. If performed well on all selection criteria. Vortex and Optichamber also performed well. Volumatic showed the lowest score.**

*Keywords: Asthma; COPD; Valved Holding; Aerochamber*

## Introduction

Inhalation therapy is the cornerstone of the drug treatment of patients with asthma and chronic obstructive lung disease (COPD). There are four main groups of dosage forms: metered dose inhalers (PDMIs), dry powder inhalers (DPI), soft mist inhalers and nebulizers. In line with (inter) national guidelines, PDMIs are usually prescribed in combination with an inhalation chamber in order to optimize lung deposition, to facilitate use and reduce the chance of local side effects, especially for inhaled corticosteroids. About 600,000 patients in the Netherlands use an inhalation chamber (data on file Benu pharmacies).

The large number of available medicines and devices makes it almost impossible to have sufficient knowledge of each individual medicine and device, especially for general practitioners [1,2]. Patient compliance in COPD and asthma is multi factorial, including understanding of the disease by the patient, physician-pharmacist-patient interactions, incorrect inhalation techniques and personal factors by the patient. A poor inhalation technique may lead to sub optimal treatment, more exacerbations, hospitalizations and higher treatment costs [3,4].

Reducing the number of medicines and devices, based on rational criteria, allows physicians and pharmacists to build experience with a more limited set of medicines and to standardize the inhalation instructions.

This study aims to develop a set of rational and transparent selection criteria for inhalation chambers.

# Methods

## Research question

The authors of the present article were members of the Expert Group (Working Party) of the Dutch Lung Association. The aim of this Working Party (consisting of pulmonologists, general practitioners, researchers and hospital- and community pharmacists) was to provide criteria for the selection of inhalation chambers for the maintenance treatment of COPD in the Netherlands. The first draft of the article was prepared by authors JK, PH and RJ and extensively discussed with author RD.

## Inclusion and exclusion criteria

This analysis was performed to compare inhalation chambers, in combination with PMDIs.

## Applied methodology

In this study inhalation chambers are compared by means of the SOJA method

The System of Objectified Judgement Analysis (SOJA) method is a model for rational drug selection. The relevant selection criteria for inhalation chambers are defined and judged by a panel of experts and each selection criterion is given a relative weight. The more important a selection criterion is considered, the higher the relative weight that is given to that criterion. The ideal properties for devices are determined and each device is scored as a percentage of the score of the ideal device for all selection criteria. The devices with the highest total score are most suitable for formulary inclusion [5].

## Selection criteria

The following selection criteria were applied.

table a

| Criterion  | Relative weight |
|--|-----------------|
| Transparency                                       | 50              |
| Feedback system in case of too forceful inhalation | 50              |
| Antistatic properties                              | 300             |
| Dose delivery                                      | 300             |
| Availability of mouth-masks                        | 50              |
| Easy to carry                                      | 100             |
| Suitability for children                           | 50              |
| Included in SPC's of pMDIs                         | 100             |
| Total score  | 1000            |

The following devices were included in the analysis.

table b

Aerochamber  
Inspirachamber  
Optichamber  
Volumatic  
Vortex

The Spacechamber was not included in the set of valved holding chambers, because it is no longer available in the Netherlands.

The Able Chamber was also not included, because this is not available in the Netherlands.

## Selection criteria

### Transparency

- Transparency of the spacer is an advantage. The patient then experiences more feedback in the sense that the spray and the valve are visible from the PMDI. If the spray is not visible, the care recipient might press the PMDI a second time if in doubt.
- Furthermore, the user notices more quickly that the spacer chamber is dirty and has to be cleaned.
- The more transparent, the better. An inhalation chamber which is completely transparent scores 100%, whereas a chamber, which is not at all transparent does not score for this criterion.
- Inhalation chambers, which are not fully transparent score in between 0% and 100%.

### Feedback system

- Feedback when inhaling too strongly is nice because it can prevent deposition in the throat. It is therefore an advantage when the patient receives feedback in case of inhaling too strongly.
- Some inhalation chambers have a feedback system in the form of a whistle signal. This must be interpreted correctly because the whistle signal is audible if you inhale too forcefully.
- In addition, the whistle signal depends on the type of chamber and the internal resistance of the pMDI.
- Internal resistance of the chamber plays a role in this.

### Antistatic properties

The antistatic properties have the advantage that significantly less aerosol particles are lost to the spacer wall. This means that the available dose for the patient is considerably less if the spacer does not have antistatic properties.

# Methods

The spacer must be cleaned in a mild detergent solution weekly and either rinsed with water depending of the antistatic properties (drip and dry method) or cleaned in a mild detergent solution without rinsed water (drip and rinsed method). Only the antistatic spacers can be rinsed with water. In case of non-antistatic spacers, it is advised to clean without rinsing water.

## Dose delivery

- Unfortunately, no clinical studies are available regarding the effects of the devices on clinically relevant criteria, such as exacerbations, hospitalizations or mortality.
- The only studies that are available deal with the effects on dose delivery of bronchodilators and inhaled corticosteroids.
- This was scored as follows: the inhalation chambers with the lowest delivery did not score, whereas the one with the highest delivery was assigned 100%. The scores for the other devices were obtained by linear intrapolation.

## Availability of mouth masks

Some categories of patients may benefit from a mask instead of a mouth-piece, such as babies and patients with dementia. There are no comparative data to the best of our knowledge. Ranking will depend on the setting of the patients (young children, elderly patients in a nursing home).

## Easy to carry

- It is important that an inhalation chamber has a limited size, in order to make it easy to carry. The lower the volume, the better.
- The chamber with the lowest volume received 100% and the chamber with the highest volume did not score.

## Suitability for children

It is important that a chamber is approved for use in children. This was scored as such.

## Included in SPC's of PMDI's

The European Medicines Agency (EMA) recommends that with each PMDI data are shown on the in vitro outcomes with at least one specific spacer. On the basis of this data an inhalation chamber is recommended in the Summary of Product Characteristics (SPC) of the PMDI. In case of substitution of a spacer solid equivalence data must be shown by the producer of dose delivery and particle size distribution. Also the Medicines Evaluation Board (CBG) takes the position (found in the SPC of various generic PMDI's) that spacers cannot be interchanged because "changing spacers may result in changes in dose delivery to the lungs.

It is therefore an advantage when an inhalation chamber has been tested in a wide range of PMDI's. This was scored as follows

Included in the SPC of

|            |     |
|------------|-----|
| SABA:      | 15% |
| SAMA:      | 15% |
| SABA/SAMA: | 10% |
| LABA:      | 10% |
| LAMA:      | 10% |
| LABA/LAMA: | 10% |
| LABA/ICS:  | 10% |
| ICS:       | 10% |
| Triple:    | 10% |

# Results

## Transparency

The properties of the inhalation chambers are summarized below.

*table c*

|                | Fully transparent | Semi transparent | Non transparent | Score |
|----------------|-------------------|------------------|-----------------|-------|
| Aerochamber    | Yes               |                  |                 | 100%  |
| Inspirachamber |                   | Yes              |                 | 75%   |
| Optichamber    | Yes               |                  |                 | 100%  |
| Volumatic      | Yes               |                  |                 | 100%  |
| Vortex         |                   |                  | Yes             | 0%    |

## Feedback system

The properties of the inhalation chambers are summarized below.

*table d*

|                | Whistle<br>(80%) | Visible flow indicator for the healthcare provider<br>(20%) | Score |
|----------------|------------------|---|-------|
| Aerochamber    | Yes              | Yes   | 100%  |
| Inspirachamber | Yes              | Yes*  | 85%   |
| Optichamber    | Yes              | Yes   | 100%  |
| Volumatic      | No               | No  | 0%    |
| Vortex         | No               | No  | 0%    |

The visual flow indicator shows the inspiration and expiration flow of the patient during the inhalation which is very helpful to instruct the patient in a proper way. One manufacturer\* build the flow indicator only in the mouth mask and this is still useful to check if the mouth mask is placed correctly but gives no flow indicator information without this mouth mask. Mouth masks are used in a minority of patients.

## Antistatic properties

The antistatic properties of the valved holding chambers are quite different. This is because there are spacers available that do bear the label that they are anti-static, but the degree of the anti-static character differs considerably. In addition, there are also spacers on the market that do not have these anti-static properties.

*table e*

|                | Not antistatic | Limited antistatic | Antistatic | Score |
|----------------|----------------|--------------------|------------|-------|
| Aerochamber    |                |                    | x          | 100%  |
| Inspirachamber |                | x                  |            | 50%   |
| Optichamber    |                |                    | x          | 100%  |
| Volumatic      | x              |                    |            | 0%    |
| Vortex         |                |                    | x          | 100%  |

## Cleaning procedure

The desired cleaning procedure depends on the antistatic properties of the respective chambers. If the chamber is not or only slightly antistatic, it should be cleaned in a soap solution, not rinsed and then allowed to air dry. The dried soap solution provides the antistatic character. This does not only apply to weekly cleaning but also to the first use [6]. When the spacer is antistatic, it can be rinsed during the weekly cleaning and special pre-treatment before first use is not necessary.

# Results

## Dose delivery

The study of Hagedoorn, et al. [6] was used for comparison of the inhalation chambers. Delivered doses of salbutamol (Ventolin) and beclomethasone (Qvar) from different antistatic valved holding chambers after rinsing or drip-drying. The highest delivery was found for beclomethasone drip dried for the Vortex (67%). This was assigned a score of 100%. The lowest delivery was seen for the salbutamol drip dried for the Optichamber (13%). This did not score. The scores were calculated as follows.

*table f*

|                | Salbutamol rinsed | Salbutamol drip dried | Beclomethasone rinsed | Beclomethasone drip dried |
|----------------|-------------------|-----------------------|-----------------------|---------------------------|
| Aerochamber    | 35% (32-37)       | 33% (32-36)           | 61% (54-67)           | 58% (50-62)               |
| Inspirachamber | 13% (13-14)       | 27% (15-36)           | 31% (21-40)           | 64% (53-70)               |
| Optichamber    | 22% (17-26)       | 19% (16-20)           | 52% (41-56)           | 49% (42-56)               |
| Volumatic      | NA                | NA                    | NA                    | NA                        |
| Vortex         | 30% (26-35)       | 32% (26-38)           | 58% (47-70)           | 67% (56-75)               |

*table g*

|                | Salbutamol rinsed | Salbutamol drip dried | Beclomethasone rinsed | Beclomethasone drip dried | Mean | Score after intrapolation |
|----------------|-------------------|-----------------------|-----------------------|---------------------------|------|---------------------------|
| Aerochamber    | 41%               | 37%                   | 89%                   | 83%                       | 63%  | 100%                      |
| Inspirachamber | 0%                | 26%                   | 33%                   | 93%                       | 38%  | 60%                       |
| Optichamber    | 15%               | 9%                    | 72%                   | 67%                       | 41%  | 65%                       |
| Volumatic      | 0%                | 0%                    | 0%                    | 0%                        | 0%   | 0%                        |
| Vortex         | 31%               | 33%                   | 83%                   | 100%                      | 62%  | 98%                       |

## Availability of mouth masks

*table h*

|                | Masks   | Score |
|----------------|---|-------|
| Aerochamber    | Baby / Children 1 - 4 / Children > 5 / Adults small / Adults normal / Adult large | 100%  |
| Inspirachamber | Soother / Inspiramask   | 100%  |
| Optichamber    | Adults / Children   | 100%  |
| Volumatic      |   | 0%    |
| Vortex         | 0 - 2 years / 2 - 4 years / > 4 years / Adults                                    | 100%  |

## Easy to carry

*table i*

|                | Volume | Score |
|----------------|--------|-------|
| Aerochamber    | 149 ml | 98%   |
| Inspirachamber | 161 ml | 97%   |
| Optichamber    | 140 ml | 100%  |
| Volumatic      | 750 ml | 0%    |
| Vortex         | 194 ml | 91%   |

## Suitability for children

*table j*

|                | Baby | Child | Adults | Score |
|----------------|------|-------|--------|-------|
| Aerochamber    | x    | x     | x      | 100%  |
| Inspirachamber | x    | x     | x      | 100%  |
| Optichamber    | x    | x     | x      | 100%  |
| Volumatic      | x    | x     | x      | 100%  |
| Vortex         | x    | x     | x      | 100%  |

Obviously, this criterion is only relevant for asthma and not for COPD treatment.

# Results

## Included in SPC's of PMDIs

There are considerable differences between the inhalation chambers regarding the clinical documentation in the SPCs.

Table 6

|           | Aerochamber   | Inspirachamber | Optichamber | Volumatic                                       | Vortex     |
|-----------|---|----------------|-------------|---|------------|
| SABA      | Salbutamol  |                |             | Ventolin  | Salbutamol |
| SAMA      | Ipratropium   |                |             |   |            |
| LABA      | Salmeterol  |                |             | Salmeterol                                      |            |
| LAMA      |   |                |             |   |            |
| LABA/LAMA |   |                |             |   |            |
| LABA/ICS  | Airflusal<br>Fluticasone/salmeterol<br>Flutiform<br>Foster<br>Seretide<br>Symbicort |                |             | Airflusal<br>Fluticasone/salmeterol<br>Seretide |            |
| ICS       | Alvesco   |                |             | Flixotide                                       |            |
| Triple    | Trimbow   |                |             |   |            |
| Score     | 80%   | 0%             | 0%          | 45%   | 15%        |

## Score

The SOJA score for inhalation chambers in COPD and asthma treatment is presented below.

Table 7

|                           | Aerochamber | Inspirachamber | Optichamber | Volumatic | Vortex | Weight |
|---------------------------|-------------|----------------|-------------|-----------|--------|--------|
| Transparency              | 50          | 38             | 50          | 50        | 0      | 50     |
| Feedback system           | 50          | 43             | 50          | 0         | 0      | 50     |
| Antistatic properties     | 300         | 150            | 300         | 0         | 300    | 300    |
| Dose delivery             | 300         | 180            | 195         | 0         | 294    | 300    |
| Mouth mask                | 50          | 50             | 50          | 0         | 50     | 50     |
| Easy to carry             | 98          | 97             | 100         | 0         | 91     | 100    |
| Suitability for children  | 50          | 50             | 50          | 50        | 50     | 50     |
| Included in SPCs of PMDIs | 80          | 0              | 0           | 45        | 15     | 100    |
| Score                     | 978         | 608            | 795         | 145       | 800    | 1000   |

# Discussion

## Applied methodology

This was done by means of the SOJA method, which is a well-established rational and transparent way of selecting medicines (or in this case inhalation chambers) within a therapeutic class from a formulary perspective.

In the SOJA method, selection criteria for a given group of drugs (or in this case devices) are prospectively defined and the extent to which each individual device fulfills the requirement for each criterion is studied. Each criterion is given a relative weight (i.e., the more important a given selection criterion is considered to be, the higher is the relative weight given to that criterion). Both the relative scores for each drug for each selection criterion and the relative weight of each criterion are determined by a panel of experts in this field. The properties of all drugs are compared to the hypothetical 'ideal' device from that group, which is assigned the full relative weight for each criterion. The ideal inhalation chamber will have to score 100% on all selection criteria.

In the published SOJA scores, 1000 points are divided over the criteria that are considered to be relevant for a particular group of drugs. In the interactive program, the scores for each drug have been determined by a group of experts and the user is free to assign his own relative weight to each criterion using any scale he wishes. The program then computes the ranking scores for the drugs in the group.

## Outcome

Substantial differences were seen in the overall scores, Aerochamber showed the highest score, followed by Vortex and Optichamber. Volumatic showed by far the lowest score.

## Strength and limitations of the methodology

In most cases SOJA scores are derived from a large number (between 50 and 400) of references, including double-blind comparative studies, systematic reviews and meta-analyses. In this case no clinical studies are available regarding the effects of valved inhalation chambers on clinically relevant endpoints, such as exacerbations and hospitalizations, let alone comparative studies between two or more inhalation chambers on these endpoints. That is the reason why so few references were included in this article.

It should be taken into consideration that this analysis is limited to the inhalation chambers. In clinical practice, patient related factors play an important role, such as personal preferences of the patient.

The evaluation of criteria in the SOJA method is highly standardized in

order to promote unbiased judgment of drugs from various pharmacotherapy categories based on clinically relevant criteria. There will always be room for debate whether or not the correct scoring system was used for each criterion and judgment may be arbitrary for most, if not all, criteria. This is the case with any method used to quantify properties of drugs or devices. The SOJA method is intended as a tool for rational drug decision making, forcing clinicians and pharmacists to include all relevant aspects of a certain group of drugs, thereby preventing formulary decisions being based on only one or two criteria. The outcome of this study should be seen as the basis for discussions within formulary committees and not as an absolute truth.

Obviously, the score depends on the relative weight that is assigned to each individual selection criterion. Therefore an interactive program is available, which makes it easy for local and regional formulary committees to assign personal weights to each selection criterion by individual members. If a physician or pharmacist considers individual criteria as totally irrelevant, this criterion may be assigned 0 points, thereby ignoring this criterion. This could be the case for the criterion availability of mouth masks, which are relevant for a small minority of patients (such as babies and patients with dementia).

It offers advantages for the healthcare provider when an inhalation chamber can be autoclaved. This makes it possible to re-use the inhalation chamber during lung function tests. This criterion was not included in our set of criteria, because these are aimed at patients and not at healthcare providers.

In the most unfavorable case, therefore a factor 4 difference between the "best and worst" combination of PMDI and inhalation chamber, which should be relevant, but the clinical impact was not investigated. The major differences between the spacers are largely in the degree of their anti-static character, despite the fact that they are all labeled as anti-static. This was scored under the criterion dose delivery

To the best of our knowledge, there are no comparative studies comparing VHCs to each other on clinical endpoints like dyspnea scores and exacerbations.

The main outcome of this matrix may be that major steps can be made in reducing the number of different inhalation chambers, thereby allowing standardized and optimal patient information, which can be the same provided by all caregivers.

The set of selection criteria was determined by the panel of experts in the Dutch working party after extensive discussions.



# Discussion

## Several potential selection criteria were not used in this analysis

### Acquisition cost

Acquisition cost was not taken into account, because this varies with time. In practice acquisition cost is of course an important selection criterion, especially because there are very limited differences between the medicines from a clinical perspective. Exclusion of this criterion also makes this comparison more internationally applicable.

### Patient preference

The results of these studies are highly dependent on study design. Most studies (if not all) show a preference for the device from the sponsor of the study. Besides this, no studies are available comparing all devices.

### Ease of use

The same limitations apply as described under patient preference.

### Environmentally friendly

This criterion may be important from a society perspective, but there is very little, if any, published information on the inhalation chambers.

The disposable spacers are not included in these scores because they are rarely or not prescribed and there is also insufficient data available to include them for the SOJA method.

# Conclusions

Large differences are observed in the scores of the inhalation chambers. Aerochamber showed by far the highest score, followed by Vortex and Optichamber. Volumatic showed by far the lowest score. It seems logical to limit the number of different devices that are used in the treatment of COPD through regional or local formulary decisions. This results in a smaller number of different inhalation chambers used by individual patients, which will likely result in better treatment results through fewer inhalation errors. Also, reducing the number of different devices prescribed by physicians and dispensed by pharmacists will make it easier to standardise inhalation instructions, which may even further improve treatment outcomes.

Several authors recommended not to switch easily between valved inhalation chambers, because of differences in dose delivery [7-9].

## Authors

- Technologist Inhalation, Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, The Netherlands
- Pulmonologist, Radboud University Medical Center, Nijmegen, The Netherlands
- BENU Pharmacies, Maarssen, The Netherlands
- Hospital Pharmacist, Clinical Pharmacologist Sittard, The Netherlands

## Bibliography

- López-Campos JL, et al. "Status of and strategies for improving adherence to COPD treatment". *International Journal of Chronic Obstructive Pulmonary Disease* 14 (2019): 1503-1515.
- Gardener AC, et al. "Support needs of patients with COPD: a systematic literature search and narrative review". *International Journal of Chronic Obstructive Pulmonary Disease* 13 (2018): 1021-1035.
- Usmani OS, et al. "Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes". *Respiratory Research* 19:1 (2018): 10.
- Kocks JWH, et al. "Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD". *NPJ Primary Care Respiratory Medicine* 28 (2018): 43.
- Janknegt R and Steenhoek A. "The System of Objectified Judgement-Analysis. A tool in rational drug selection for formulary purposes". *Drugs* 53 (1997): 550-562.
- Hagedoorn P, et al. "A comparative analysis of changes in pMDI drug dose delivery before and after detergent coating using five antistatic valved holding chambers". *The Journal of Allergy and Clinical Immunology: In Practice* 8 (2020): 1124-1125.
- Hagedoorn P and Grasmeyer F. "Ook antistatische voorzetkammers zijn niet één-op-een uitwisselbaar bij inhalatietherapie". *COPD and Astma Bulletin Huisartsgeneeskunde* (2020): 1.
- Dekhuijzen PNR and Hagedoorn P. "Voorzetkamer nooit zomaar inwisselen voor een andere". *Pharmaceutisch Weekblad* 135 (2020): 46.
- Dissanayake S, et al. "Are valved holding chambers (VHCs) interchangeable? An in vitro evaluation of VHC equivalence". *Pulmonary Pharmacology and Therapeutics* 48 (2018): 179-184.